OncoNano Medicine, Inc., a biotechnology company developing ultra pH-sensitive micelles for the detection, staging and treatment of cancer, today announced two poster presentations – including a late-breaking abstract – for the Society for the Immunotherapy of Cancer (SITC) Annual Meeting to be held in National Harbor, Maryland, November 6-10. OncoNano’s core technology is a library of tunable, ultra pH-sensitive micelles that exist intact under baseline physiological pH conditions but dissociate to release their payload under different, predesignated pH levels... (read more)

OncoNano Medicine, Inc. today announced that it has been awarded $15.4 million from the Cancer Prevention and Research Institute of Texas (CPRIT) to advance ONM-500, one of OncoNano’s innovative oncology product candidates. In ONM-500, OncoNano leverages its proprietary pH-sensitive micelle technology to deliver antigens while activating innate immunity for the treatment of cancers caused by the human papilloma virus (HPV). This grant award adds to an initial $6 million grant that the company received from CPRIT in 2014 for advancement of the company’s ONM-100, where OncoNano’s micelle technology is being used to intraoperatively image tumors during surgical resection, currently in Phase 2 clinical trials... (read more)

Salem Partners, LLC (“Salem Partners”) is pleased to announce the successful completion of a $35 million senior loan for its client, Urban Mining Company (“UMC”) and its investors and affiliates. UMC presented Salem Partners with the challenge to structure a credit product that would provide enough proceeds to refinance its existing real estate debt, finish its mission critical manufacturing facility in the Austin / San Marcos region of Texas and capitalize all transaction and interest costs (a proceeds level which was unavailable by typical bank lenders) all within a tight time frame... (read more)

OncoNano Medicine, Inc. today announced the completion of its Phase 1a clinical trial and expansion into Phase 1b to evaluate ONM-100, the intravenously administered imaging agent to detect tumors and metastatic lymph nodes in solid cancers during surgery. The results of Phase 1a will be included in a poster presentation at the San Antonio Breast Cancer Symposium being held on December 4-8, 2018... (read more)

​AsclepiX Therapeutics, Inc., a biopharmaceutical company focused on developing vital new therapies based on a novel peptide platform, today announced that it has raised $5 million in Convertible Note funding, led by Barer & Son Capital with additional funds from Rapha Capital Management, Salem Partners, TEDCO, and Piedmont Capital Partners. In concert with the funding, AsclepiX expanded its board to add Josh Barer, Kevin Slawin, MD, and Sapna Srivastava, PhD, to the founding members Aleksander Popel, PhD and Jordan J. Green, PhD and CEO Wendy Perrow, MBA... (read more)

Sebacia, Inc., a privately held, commercial stage dermatology and aesthetics company, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance for its lead product, Sebacia Microparticles. This significant achievement is a milestone in the treatment of acne and follows the company’s completion of its pivotal study, which clearly demonstrated clinical efficacy and safety of Sebacia Microparticles, and its 510(k) submission to the FDA in June 2018... (read more)

Synteract has snapped up the specialty contract researcher Cu-Tech, with plans to establish a dedicated center for the development of dermatology products and make the midsized, global CRO into a destination for skin-care clinical trials.
​
The Mountain Lakes, New Jersey-based Cu-Tech has managed more than 130 dermatology trials over the past two decades, covering a variety of indications... (read more)

Salem Partners, LLC is pleased to announce the successful completion and placement of a $54 million revolving credit facility for its client, Eisenhower Property Group (“EPG”). Salem Partners advised EPG on an exclusive basis and selected a credit hedge fund to provide the financing. First closing of the facility occurred on June 13th, 2018.

Jeff Barcy, Managing Director of Salem Partners’ real estate investment banking group, and Parker Bennett, Director of real estate investment banking, led negotiations and... (read more)

SOUTHLAKE, TX - OncoNano Medicine, Inc. today announced the closing of a $11.7 million Series A financing. The transaction was arranged by Salem Partners, who also participated as a principal investor. The Series A funding supplements a $6 million grant previously received from the Cancer Prevention and Research Institute of Texas (CPRIT). The funding will be used to support the company’s continued clinical development of a new class of pH-activated compounds that digitalize and exploit the variability of pH in disease indications such as cancer. The company is also pleased to announce the appointment of five established industry leaders to its Board of Directors... (read more)

LOS ANGELES, CA - Salem Partners, LLC is pleased to announce the successful completion of a $40 million convertible preferred equity placement for its client, Four Springs Capital Trust (“FSCT” or “Four Springs”) with Guggenheim Investments (“Guggenheim”).  The transaction closed on January 23th, 2018, with Salem Partners acting as the financial advisor and investment bank to FSCT.  Jeff Barcy, Managing Director of Salem Partners’ real estate investment banking group, and Parker Bennett, Director of real estate investment banking, led negotiations... (read more)

HONOLULU, HI - ​Salem Partners, through one of its affiliated entities, has sold a Walgreens flagship store located at 1500 Kapiolani Boulevard in Honolulu for $42.25 million, one of the highest sales prices for a store in Walgreens’ history... (read more) 

LOS ANGELES, CA -- ​Salem Partners is pleased to announce the successful completion of a programmatic joint-venture in the real estate / multifamily sector for its client, Grand Peaks Properties, Inc. (“GPP”). The joint-venture is between GPP and a global family office with the objective to aggregate $1 billion of multifamily assets.  GPP is a vertically-integrated, national operator... (read more)

​LOS ANGELES, CA - The Honolulu City Council has approved a $700 million, 36-story mixed-use tower across from the Convention Center to be developed by Los Angeles-based Salem Partners. Located at the intersection of Kapiolani Boulevard and Atkinson Drive, Mana`olana Place is the first approved project in the city’s newly adopted Ala Moana transit-oriented district and is expected to be a catalyst for further investment in the area. The iconic tower’s 505,000 square feet will house a 125-room ultra-luxury hotel.... (read more)

LOS ANGELES, CA - Salem Partners is pleased to announce the successful completion of a large programmatic joint-venture in the real estate / medical office sector for its client, Everest Medical Core Properties (“Everest MCP”). The joint-venture is between Everest MCP and a major, U.S. based real estate private equity firm.... (read more).

HONOLULU, HI - ​Walgreens’ Hawaii flagship store in Honolulu won this year’s highest level of recognition in the retail store design category of the International Council of Shopping Centers’ awards competition for U.S. design and development... (read more)

ATLANTA, GA - December 14, 2015 --- Femasys Inc., a developer of innovative medical devices for the women’s healthcare market today announced the appointment of Todd A. Creech as Chief Financial Officer. Mr. Creech will serve as Femasys’ principal financial and... (read more)

HONOLULU, HI - Walgreens has sold its flagship Hawaii store across from Ala Moana Center in Honolulu, along with the adjacent Heald College Building on Kapiolani Boulevard, to Los Angeles-based investment bank and wealth management firm Salem Partners for a total of $73.5 million...(read more)